Articles tagged with Inflammatory Disorders
Researchers present a roadmap for developing Tregs as adaptable therapies to restore immune balance and support tissue repair. This approach holds promise for treating conditions such as metabolic and cardiovascular disease, as well as neurodegeneration.
New therapies using regulatory T cells, known as Tregs, could target diseases with inflammation, such as cancer and autoimmune conditions. Early evaluations show good tolerance and safety profiles, but precision is key to tailoring treatments for specific patients.
A team of international researchers has identified a previously unknown genetic cause of Crohn's disease in children, specifically pathogenic variants in the BIRC3 gene. The study found that loss of BIRC3 function leads to dysregulation of the RIPK1 signaling pathway, promoting chronic inflammations and increasing epithelial cell death.
Scientists have identified a unique chimeric RNA called UBA1-CDK16 that plays important roles in women's blood cell development and disease severity. The findings suggest the chimeric RNA may serve as a natural brake to protect women from excessive autoimmune activity.
A new study found that chronic pancreatitis (CP) impairs multiple quality-of-life domains, including mobility, self-care, daily activities, mental health, and pain. Employment status is a powerful protective factor, while older age correlates with milder QoL impairments.
A new review highlights advances in preventing bone loss in people with rheumatoid arthritis, showing that modern antirheumatic therapies can significantly reduce both localized erosions and generalized bone loss. Emerging imaging technologies like HR-pQCT have been found to detect subtle bone erosions earlier and more sensitively.
A new study has found that standard antibody-based tests can fail to detect all gluten residues in barley beer, leading to concerns about the safety of gluten-free products. Researchers developed a new mass spectrometry method to identify celiac disease-active peptides, which were found in some 'gluten-free' beers.
A new review highlights that vitamin D deficiency is common and clinically important in patients with inflammatory rheumatic diseases, but the current evidence does not support a direct disease-modifying effect. Vitamin D supplementation shows modest benefits in some patients, particularly those with low baseline vitamin D levels.
Researchers have found a widely available drug combination to be an effective treatment for patients with systemically active Sjögren's disease. The combination of leflunomide and hydroxychloroquine reduced disease activity while maintaining a favorable safety profile.
Researchers at Garvan Institute of Medical Research discovered key immune cells malfunction in mevalonate kinase deficiency (MKD), a rare but devastating autoinflammatory disorder. Current treatments targeting inflammatory signals produced by macrophages fail in half of patients, but JAK inhibitors may provide relief.
A new study from Cornell University found that delaying the first dose of hepatitis B vaccine after birth leads to increased infections and higher healthcare costs. The longer the delay, the more severe the consequences for newborns, who are at high risk of developing chronic infections and premature death.
A protein interaction between iNOS and IRG1 has been identified as a key regulator of the immune response. This discovery could lead to new treatments for conditions such as cardiovascular disease, arthritis, and Crohn's disease.
Researchers found that patients taking TNF inhibitors reported better energy levels and mood, while those on IL-6 and JAK inhibitors showed improved physical functioning. This suggests different drug classes offer distinct advantages across quality-of-life domains.
Research found that people who spend a higher proportion of their total physical activity doing vigorous activity have substantially lower risks of all eight serious health conditions. The benefits of vigorous activity remained even when the amount of time was modest.
Researchers identified distinct genetic sequences that propel critical memories into years-long timeframes underpinning chronic disease. The study provides valuable inroads for developing new therapeutic strategies for chronic inflammation.
A drug already in clinical trials for hepatitis C has been found to also prevent hepatitis E virus replication, offering new hope for a treatment option. The discovery was made using a library of nucleotide/nucleoside analogues and preclinical models.
University of Pittsburgh scientists discovered a way to fight insulin resistance and diabetes by protecting a special type of immune cell in fat tissue. By improving insulin sensitivity in mice, the research reveals a potential new treatment path for type 2 diabetes that could supplement GLP-1 drugs.
A new study found that while the number of pancreatitis-associated deaths among the elderly decreased between 1992 and 2021, the total cases rose significantly due to population growth. The age-standardized incidence rate per 100,000 fell from 100.21 in 1992 to 85.20 in 2021.
Salk Institute scientists discover that dietary supplementation of the amino acid methionine protects infected mice against inflammation-related wasting, blood-brain barrier dysfunction, and death. Methionine boosts kidney filtration, reducing circulating cytokine levels and improving disease outcomes.
A new study by King's College London found that early treatment with abatacept can delay rheumatoid arthritis (RA) onset in people at high risk for several years. The benefits persist even after treatment has stopped, potentially reducing the number of years people live with symptoms and complications.
Researchers found that inadequate characterization of the menstrual cycle in studies contributes to conflicting results. A new study aims to investigate the relationship between hormonal fluctuations and physical exercise, seeking to broaden understanding of women's immunity.
The study demonstrates that fexofenadine reduces cartilage degradation, inflammation, and senescence in mice models for OA and IVDD. Pharmacological inhibition of cPLA2 preserves cartilage structure and improves behavioral outcomes.
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at UMC Utrecht are developing a predictive model to accurately predict disease progress in juvenile dermatomyositis. The Interferon Score aims to identify which children can safely reduce medication and which require intensified treatment.
Researchers from Intermountain Health have found that GLP-1 receptor agonists do not increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides. Patients taking these medications had a four times lower risk of developing pancreatitis compared to those not on the medication.
Scientists have discovered that immune cells shed their glycocalyx layer to move into tissues, changing the understanding of inflammatory skin diseases like psoriasis. This finding may lead to new approaches in developing drugs targeting immune cell movement and treating infections and inflammatory diseases.
Researchers discovered that Shigella flexneri uses three effectors to disable host defense pathways, allowing the pathogen to replicate and evade the immune system. This study offers new insights into developing vaccines and targeted therapies for inflammatory colitis, a significant public health challenge.
Case Western Reserve University researchers discovered pseudo leukotrienes, which may be the dominant players in the inflammatory cascade that causes disease. The findings open new avenues for treating asthma and other inflammatory diseases.
Researchers have identified 57 unique proteins in urine that can indicate active damage to the kidneys, enabling non-invasive monitoring of lupus nephritis. This breakthrough could transform diagnosis and treatment for millions worldwide affected by systemic lupus erythematosus.
A study by UT Arlington researchers found that state welfare policies affect joint pain trends, with states like Colorado and Hawaii seeing significant increases. In contrast, Texas saw a decrease in the educational gap despite increased pain prevalence, highlighting the need for targeted interventions.
Researchers from the Stowers Institute for Medical Research have identified a common process that powers the creation of protein formations that assemble like a 3D puzzle, triggering inflammation and cell death. This 'Catch-22' mechanism may be one of the fundamental reasons why we age.
A new study from the University of Birmingham has found that immune ageing may be a driver of rheumatoid arthritis rather than a consequence of the disease. The research detected features of immune system ageing in the earliest stages of RA, even before clinical diagnosis, suggesting that early intervention is possible.
Researchers found that immature neutrophils migrate into inflamed tissues upon stimulation by interferon-γ, suppressing inflammation and reducing tissue damage. In humans, these cells also produce interleukin-10, which increases in the blood of COVID-19 patients.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Aging cells disrupt bone renewal and repair processes, leading to weak bones and joint degeneration. Cellular senescence and inflammation are major drivers of skeletal decline, while senolytics and emerging therapies offer promising new paths for treatment.
A new drug delivery system targeting the spleen could provide more effective treatment options for lupus, a debilitating autoimmune disease. The system uses lipid nanoparticles modified with mannose to deliver medicine directly to the spleen and target critical immune cells thought to drive the disease.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Nanoparticles containing calcitriol and a protein fragment from aggrecan have been shown to regulate dendritic cell activity, reducing inflammation and swelling in RA. The treatment also delays disease onset and reduces joint damage when combined with other medications.
A groundbreaking study has uncovered the unique architecture of cells and signals inside the joint as inflammation takes hold in children with arthritis. The research provides a new way forward for understanding this condition, which affects over 10,000 children in the UK.
Researchers investigated the link between HIV treatment regimens and osteoarthritis development, revealing that certain medications like lopinavir can exacerbate OA in the knee. The study's findings have important implications for people living with HIV, highlighting the need to carefully consider treatment options.
A large cohort study has shown that supplementary treatment with statins can boost survival chances for critically ill patients with sepsis. The results indicate a 39% lower death rate over 28 days after hospital admission.
A study of twins reveals that certain bacteria in the small intestine may trigger MS. Researchers identified two specific bacteria, Lachnoclostridium sp and Eisenbergiella tayi, which are associated with the disease. The findings suggest a new potential therapeutic target for MS treatment.
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.
Researchers at La Jolla Institute for Immunology discovered that CD4+ T cells target Chikungunya virus, leading to chronic inflammation and joint pain. The study suggests that these monofunctional T cells may be the culprits behind arthritis-like symptoms in CHIKV patients.
Research from Babraham Institute uncovers importance of RNA binding proteins in regulatory T cell function. The study sheds light on how the immune system maintains balance and forms foundation for understanding age-related inflammation.
Researchers at KAIST have identified a critical protein called SLIRP that acts as an 'immune switch' regulating immune responses to viruses and autoimmune diseases. Suppressing SLIRP can alleviate abnormal immune responses in patients with Sjögren's syndrome, coronavirus, and encephalomyocarditis virus infection.
Researchers discovered that certain immune cells in the gut of refractory coeliac disease patients carry genetic mutations, driving ongoing intestinal inflammation and symptoms. The study's findings suggest a new way to diagnose and potentially treat the most severe form of coeliac disease.
Researchers discover certain skin bacteria metabolize cis-urocanic acid using enzyme urocanase, fine-tuning immune response to UV radiation. This finding opens the door to microbiome-aware sun protection, where resident microbes are considered in sun protection strategies.
A study led by the Badalona Neuromuscular Research Group found that HDAC11 deficiency reduces muscle mass loss, promotes muscle regeneration, and improves overall muscle function in aged murine models. This discovery proposes a new therapeutic strategy to slow down age-related muscular decline and promote healthier ageing.
A new study found that women with the most common autoimmune diseases die from cardiovascular disease more frequently than men. This highlights the need for improved CVD risk management in these patients.
A new report published in the COPD Foundation's journal found virtual pulmonary rehabilitation to be a safe and effective alternative for people with COPD who require supplemental oxygen. The program improved clinical outcomes and quality of life for participants, demonstrating its potential to increase access to care.
A new study found that increased perceived stress can lead to worsened respiratory symptoms and decreased quality of life in individuals with chronic obstructive pulmonary disease (COPD). The study also examined the association between stress and platelet activation, oxidative stress, and systemic inflammation.
Researchers have discovered that inhibiting the metalloprotease ADAM19 can reduce gut inflammation and cell aging markers across species. The study found that blocking ADAM19 reduced gut damage and inflammation in fruit flies, mice, and human cells, offering a promising path for creating treatments to maintain healthy tissues.
A recent study published in Journal of Experimental Medicine found that immune cells play a major role in the development of spastic paraplegia type 15. The research, led by Professor Elvira Mass and Dr. Marc Beyer, suggests that severe inflammation in the brain precedes neuronal damage and could be relevant to Alzheimer's disease.
Researchers found that immune system influences stress and fear behaviors by changing how brain cells communicate, but treatment with psychedelics can target these interactions and reduce stress-induced fear. The study suggests that psychedelics could reshape treatment for inflammatory disorders like anxiety and depression.
Researchers discovered that individuals with robust immune resilience at midlife can gain a 15.5-year survival advantage due to their ability to counter disease drivers and maintain healthy aging. The study highlights the importance of salutogenesis, or promoting health and well-being from birth to approximately age 70.
A new study from the University of Gothenburg found that titanium micro-particles are consistently present at all examined implants, even those without signs of inflammation. The researchers identified 14 genes that may be affected by these particles, but further research is needed to understand their impact on tissue health.
Researchers at the University of Florida have discovered a vitamin D nasal spray that significantly reduces nasal inflammation and improves sense of smell in mice. This study suggests a new potential treatment for humans suffering from loss of smell due to inflammation, which is often caused by cigarette smoke or COVID-19.
A new study reveals that YTHDF1 plays a crucial role in suppressing immune-mediated liver injury and modulating inflammatory responses. YTHDF1 deficiency exacerbates liver damage, inflammation, and proinflammatory cytokine production.